PH12013501723A1 - Phosphoramidate derivatives of 5 - fluoro - 2 1 - deoxyuridine for use in the treatment of cancer - Google Patents

Phosphoramidate derivatives of 5 - fluoro - 2 1 - deoxyuridine for use in the treatment of cancer

Info

Publication number
PH12013501723A1
PH12013501723A1 PH1/2013/501723A PH12013501723A PH12013501723A1 PH 12013501723 A1 PH12013501723 A1 PH 12013501723A1 PH 12013501723 A PH12013501723 A PH 12013501723A PH 12013501723 A1 PH12013501723 A1 PH 12013501723A1
Authority
PH
Philippines
Prior art keywords
cancer
treatment
deoxyuridine
fluoro
cells
Prior art date
Application number
PH1/2013/501723A
Other languages
English (en)
Inventor
Gonczy Blanka
Mcguigan Christopher
Balzarini Jan
Slusarczyk Magdalena
Murziani Paola
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45841523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013501723(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1103582.1A external-priority patent/GB201103582D0/en
Priority claimed from GBGB1105660.3A external-priority patent/GB201105660D0/en
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Publication of PH12013501723A1 publication Critical patent/PH12013501723A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PH1/2013/501723A 2011-03-01 2012-02-29 Phosphoramidate derivatives of 5 - fluoro - 2 1 - deoxyuridine for use in the treatment of cancer PH12013501723A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1103582.1A GB201103582D0 (https=) 2011-03-01 2011-03-01
GBGB1105660.3A GB201105660D0 (en) 2011-04-01 2011-04-01 Chemical compounds
PCT/GB2012/050457 WO2012117246A1 (en) 2011-03-01 2012-02-29 Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
PH12013501723A1 true PH12013501723A1 (en) 2013-10-07

Family

ID=45841523

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2013/501723A PH12013501723A1 (en) 2011-03-01 2012-02-29 Phosphoramidate derivatives of 5 - fluoro - 2 1 - deoxyuridine for use in the treatment of cancer
PH12015500485A PH12015500485A1 (en) 2011-03-01 2015-03-05 Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH12015500485A PH12015500485A1 (en) 2011-03-01 2015-03-05 Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer

Country Status (28)

Country Link
US (7) US8933053B2 (https=)
EP (4) EP3447061B1 (https=)
JP (1) JP5978232B2 (https=)
KR (1) KR101885940B1 (https=)
CN (2) CN104974206B (https=)
AU (1) AU2012223012C1 (https=)
BR (1) BR112013021986B1 (https=)
CA (1) CA2828326C (https=)
CL (1) CL2013002517A1 (https=)
CY (2) CY1117445T1 (https=)
DK (3) DK3447061T3 (https=)
ES (4) ES2569185T3 (https=)
HR (2) HRP20160346T1 (https=)
HU (2) HUE029022T2 (https=)
IL (1) IL228169A (https=)
LT (1) LT3447061T (https=)
MX (1) MX339822B (https=)
NZ (1) NZ615270A (https=)
PH (2) PH12013501723A1 (https=)
PL (3) PL3447061T3 (https=)
PT (2) PT3447061T (https=)
RS (2) RS62721B1 (https=)
RU (1) RU2614406C2 (https=)
SG (1) SG192841A1 (https=)
SI (2) SI2681227T1 (https=)
SM (2) SMT202100715T1 (https=)
WO (1) WO2012117246A1 (https=)
ZA (2) ZA201306468B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
HUE029022T2 (en) * 2011-03-01 2017-02-28 Nucana Biomed Ltd Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
SG11201503750YA (en) * 2012-11-16 2015-06-29 Univ Cardiff Process for preparing nucleoside prodrugs
WO2015013352A2 (en) * 2013-07-25 2015-01-29 Patel Hasmukh B Nucleoside phosphoramidates and phosphoramidites
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
RU2553996C1 (ru) * 2013-11-27 2015-06-20 Андрей Александрович Иващенко Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
JP2017516779A (ja) * 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
HRP20230584T1 (hr) 2014-06-25 2023-09-15 NuCana plc Prolijekovi gemcitabina
PL225283B1 (pl) 2014-07-24 2017-03-31 Univ Im Adama Mickiewicza W Poznaniu Pochodne 2,3’-anhydro-2’-deoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób wytwarzania i zastosowanie
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
HK1252245A1 (zh) * 2015-05-27 2019-05-24 Idenix Pharmaceuticals Llc 用於治疗癌症的核苷酸
US10745435B2 (en) 2015-11-16 2020-08-18 Cerecor, Inc. Nucleic acid prodrugs
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
KR102497242B1 (ko) 2016-11-13 2023-02-09 이매진 파마 당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법
EP3560943A4 (en) 2016-12-23 2020-09-02 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NUCLEOSIDIC PHOSPHATE COMPOUND, PROCESS FOR PREPARATION AND USE
RU2644156C1 (ru) * 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP2020530035A (ja) * 2017-08-08 2020-10-15 スン・ヤット−セン・ユニバーシティＳｕｎ Ｙａｔ−Ｓｅｎ Ｕｎｉｖｅｒｓｉｔｙ 多剤耐性腫瘍を治療するための方法および組成物
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) * 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
EP3763724A4 (en) * 2018-03-09 2022-01-12 Japan Science and Technology Agency SS-MODIFIED PHOSPHORIC ACID COMPOUND PRECURSOR, SS-MODIFIED PHOSPHORIC ACID COMPOUND, RESPONSE INHIBITOR AND DRUG THEREOF, AND RESPONSE INHIBITION METHOD
CN110387226A (zh) * 2018-04-20 2019-10-29 天津大学 一种用于检测肿瘤的荧光探针及用途
WO2020111279A1 (ja) * 2018-11-30 2020-06-04 国立大学法人 東京大学 カルボキシペプチダーゼ活性検出用蛍光プローブ
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
CN110840907B (zh) * 2019-08-16 2022-11-25 南京医科大学 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
AU2021331658A1 (en) * 2020-08-31 2023-03-30 Emory University 5'-substituted nucleoside monophosphates, prodrugs thereof, and uses related thereto
JP2025539267A (ja) 2022-12-07 2025-12-04 ニューカナ パブリック リミテッド カンパニー ヌクレオシド誘導体ｎｕｃ－３３７３の合成

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US1002239A (en) 1902-04-11 1911-09-05 Stromberg Carlson Telephone Telephone system.
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US3792039A (en) 1971-12-27 1974-02-12 Miles Lab Poly 2'-fluoro-2'-deoxyuridylic acid
DD279248A1 (de) 1989-01-01 1990-05-30 Akad Wissenschaften Ddr Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diamidophosphaten
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
RU2197964C2 (ru) * 1995-04-12 2003-02-10 Дзе Проктер Энд Гэмбл Компани Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CA2317505C (en) * 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
CN1390227A (zh) 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
DE10109657A1 (de) 2001-02-28 2002-09-05 Menarini Ricerche Spa Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin
JP2004534830A (ja) 2001-06-21 2004-11-18 グラクソ　グループ　リミテッド Ｈｃｖにおけるヌクレオシド化合物
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2589935A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2007020193A2 (en) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
CN101922935B (zh) 2010-07-16 2012-07-18 北京大学 一种最小互易结构干涉型全光纤陀螺仪
KR101995598B1 (ko) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
HUE029022T2 (en) 2011-03-01 2017-02-28 Nucana Biomed Ltd Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
JP5853033B2 (ja) 2011-03-01 2016-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な６，７−ジヒドロ−ピラゾロ［１，５−ａ］ピラジン−４−イルアミン誘導体
JP6855248B2 (ja) 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
EP3415149A1 (en) 2015-05-14 2018-12-19 NuCana plc Cancer treatments
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
US20230165886A1 (en) 2023-06-01
PL2681227T3 (pl) 2016-08-31
MX2013009815A (es) 2014-03-21
ES2903097T3 (es) 2022-03-31
PT3447061T (pt) 2021-12-23
SI2681227T1 (sl) 2016-04-29
SMT202100715T1 (it) 2022-01-10
AU2012223012C1 (en) 2015-09-03
NZ615270A (en) 2015-09-25
JP5978232B2 (ja) 2016-08-24
MX339822B (es) 2016-06-13
CL2013002517A1 (es) 2014-07-25
EP4023299A1 (en) 2022-07-06
HUE060127T2 (hu) 2023-02-28
SG192841A1 (en) 2013-09-30
DK3447061T3 (da) 2022-01-03
KR101885940B1 (ko) 2018-08-06
PH12015500485B1 (en) 2017-04-10
SI3447061T1 (sl) 2022-02-28
CN103403013A (zh) 2013-11-20
CY1124871T1 (el) 2022-11-25
CN104974206B (zh) 2019-08-23
WO2012117246A1 (en) 2012-09-07
US11925658B2 (en) 2024-03-12
HRP20211967T1 (hr) 2022-03-18
CN103403013B (zh) 2016-03-16
RS54776B1 (sr) 2016-10-31
EP4023299C0 (en) 2025-08-20
CA2828326A1 (en) 2012-09-07
HK1192758A1 (zh) 2014-08-29
CA2828326C (en) 2019-05-07
EP3447061A1 (en) 2019-02-27
JP2014506913A (ja) 2014-03-20
BR112013021986A2 (pt) 2016-11-16
US20140057866A1 (en) 2014-02-27
US20220023330A1 (en) 2022-01-27
US9655915B2 (en) 2017-05-23
ZA201306468B (en) 2015-04-29
BR112013021986B1 (pt) 2021-07-27
EP3447061B1 (en) 2021-11-24
EP4023299B1 (en) 2025-08-20
US20190201432A1 (en) 2019-07-04
KR20140023913A (ko) 2014-02-27
PT3031812T (pt) 2018-10-18
US11559542B2 (en) 2023-01-24
LT3447061T (lt) 2022-01-25
HUE029022T2 (en) 2017-02-28
PL3031812T3 (pl) 2018-12-31
EP3031812A1 (en) 2016-06-15
DK3031812T3 (en) 2018-09-17
RU2614406C2 (ru) 2017-03-28
US9221866B2 (en) 2015-12-29
IL228169A (en) 2016-07-31
PL3447061T3 (pl) 2022-01-31
CY1117445T1 (el) 2017-04-26
AU2012223012B2 (en) 2015-06-18
RS62721B1 (sr) 2022-01-31
RU2013143862A (ru) 2015-04-10
AU2012223012A1 (en) 2013-05-02
DK2681227T3 (da) 2016-02-22
US8933053B2 (en) 2015-01-13
EP2681227B1 (en) 2016-02-10
ES2686219T3 (es) 2018-10-16
US20160166596A1 (en) 2016-06-16
ES3039965T3 (en) 2025-10-28
ES2569185T3 (es) 2016-05-09
CN104974206A (zh) 2015-10-14
PH12015500485A1 (en) 2017-04-10
US20150183817A1 (en) 2015-07-02
US10993957B2 (en) 2021-05-04
US20170312302A1 (en) 2017-11-02
US10022390B2 (en) 2018-07-17
EP3031812B1 (en) 2018-08-01
HRP20160346T1 (hr) 2016-05-06
EP2681227A1 (en) 2014-01-08
ZA201409013B (en) 2016-02-24
SMT201600132B (it) 2016-07-01

Similar Documents

Publication Publication Date Title
PH12015500485A1 (en) Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer
ZA200709011B (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
MX2009010899A (es) Prediccion de la supervivencia al post-tratamiento en pacientes de cancer con micro-rnas.
WO2010083170A3 (en) Cell stimulation using quantum dots
WO2007134210A3 (en) Methods and compositions for the diagnosis and treatment of cancer
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
IL202292A0 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2011121453A3 (en) Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2008089397A3 (en) Adrb2 cancer markers
PH12012502215A1 (en) Anti-fgfr2 antibodies
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
MY146112A (en) Long-term feed - cancer patient
MX2013012387A (es) Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinocetan (folfiri).
HK1201462A1 (en) Methods of treating cancer
WO2007106425A3 (en) Biomarkers of the dysplastic state of cells
NZ609594A (en) Eph receptor expression in tumor stem cells
WO2008111597A1 (ja) Hlaクラスiを認識する抗体を有効成分として含有する化学療法剤耐性癌治療剤、およびその利用
WO2010062742A3 (en) Methods for freparation and use of marrow infiltrating lymphocytes (mils)
WO2007090125A8 (en) Prognostic factors for anti-hyperproliferative disease gene therapy
TW201144806A (en) Pdia4, target of cytopiloyne derivatives, for tumor diagnosis and treatment
ATE533861T1 (de) Mipol1-etv1-gen-neuanordnungen
WO2009074253A3 (en) Clofarabine dietherphospholipid derivatives
MX2009010954A (es) Actividad antitumoral de temsirolimus en cancer celular renal papilar.
WO2011130660A3 (en) Sumo as a marker of cancer development and target for cancer therapy